Steven Attia, DO
Hematology & Oncology · Jacksonville, FLNPI 1417912585
Payments from drug & device makers
Across 1,744 payments — averaging $7974.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$10.1M
- PTC Therapeutics, Inc.$1.1M
- Boehringer Ingelheim$569K
- Karyopharm Therapeutics Inc.$394K
- Incyte Corporation$265K
- Blueprint Medicines Corporation$260K
- plus $1.2M from 16 others
Across 4 payments — averaging $4600.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12K
- Pfizer$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 1,250 | $10,098,362 |
| PTC Therapeutics, Inc. | 74 | $1,099,670 |
| Boehringer Ingelheim | 26 | $569,070 |
| Karyopharm Therapeutics Inc. | 60 | $393,700 |
| Incyte Corporation | 98 | $265,166 |
| Blueprint Medicines Corporation | 35 | $260,378 |
| Epizyme, Inc. | 19 | $238,924 |
| Servier Bioinnovation | 10 | $229,426 |
| GSK | 57 | $196,683 |
| Eli Lilly | 15 | $186,422 |
| Trillium Therapeutics USA, LLC | 48 | $168,378 |
| Springworks Therapeutics, Inc. | 9 | $79,993 |
| Bavarian Nordic A/s | 7 | $68,217 |
| Adaptimmune LLC | 3 | $22,539 |
| Bayer | 6 | $13,638 |
| Pfizer | 13 | $8,541 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 8 | $7,446 |
| Merck | 2 | $906 |
| Boehringer Ingelheim International GmbH | 1 | $278 |
| Davol Inc. | 1 | $161 |
| Daiichi Sankyo Inc. | 1 | $45 |
| Foundation Medicine, Inc. | 1 | $14 |
How this compares
$13,907,957 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Jacksonville
- Sikander AilawadhiJacksonville$9.8M
- Vamsidhar VelchetiJacksonville$8.2M
- Asher Chanan KhanJacksonville$5.8M
- Yanyan LouJacksonville$4.8M
- Arnab BasuJacksonville$4.6M
- James ForanJacksonville$4.6M
- Jennifer CrozierJacksonville$3.5M
- Ayed AyedJacksonville$3.4M
- Saranya ChumsriJacksonville$3.3M
- Gerardo Colon-OteroJacksonville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.